Early Intervention Made Simple With iStent inject® W

Show Description +

During a recent symposium at EGS 2024, an expert panel reviewed important data behind early glaucoma intervention and the iStent inject W. Watch to gain insights from Laura Crawley, BSc (Hons), MB ChB (Hons), MRCP, FRCOphth; L. Jay Katz, MD; Antoine Labbé, MD, PhD; and Imran Masood, BSc, MB ChB, MRCS(Ed), FRCOphth.

Posted: 7/12/2024

Early Intervention Made Simple With iStent inject® W

During a recent symposium at EGS 2024, an expert panel reviewed important data behind early glaucoma intervention and the iStent inject W. Watch to gain insights from Laura Crawley, BSc (Hons), MB ChB (Hons), MRCP, FRCOphth; L. Jay Katz, MD; Antoine Labbé, MD, PhD; and Imran Masood, BSc, MB ChB, MRCS(Ed), FRCOphth.

Posted: 7/12/2024

Resources

Advancing Glaucoma Care: Embracing Early Interventional Approaches to Improve Patients’ Quality of Life

View Resource

10 Years & Counting: The True Test of Time!

View Resource

Prioritizing Patient Safety and the Role of Early Interventional Surgery in Glaucoma Management

View Resource

Trabecular Micro-Bypass for the Treatment of Glaucoma

View Resource

Long-Term Evidence With iStent® inject

View Resource

iStent inject® W: A Game Changer for Clinical Practice

View Resource

The Real-World Impact of iStent inject® W on Patients’ Quality of Life

View Resource

Long-Term Safety and Efficacy of the iStent® Technologies

View Resource

A Meta-Analysis of the Effect of iStent® Technologies on Visual Field Progression

View Resource

The Role of Early Intervention in Glaucoma Management

View Resource

Clinical Results From Randomized Controlled Trials

View Resource

Trabecular Micro-Bypass for the Treatment of Glaucoma

View Resource

Demystifying iStent inject® W for Glaucoma Surgery

View Resource

Trabecular Micro-Bypass Surgery for the Management of Glaucoma

View Resource

Glaucoma Disease Progression

View Resource

Early Intervention Is Best for Patients With Glaucoma

View Resource

About Glaukos International

Visit us online: glaukos.com

Contact Us

View Important Safety Information https://www.glaukos.com/en-uk/glaucoma/

References
Early Glaucoma Intervention
Florent Aptel, MD, PhD
1. Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811-821
2. Samuelson, Thomas W., et al. "Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial." American Journal of Ophthalmology 229 (2021): 220-229.

 © 2023 Glaukos Corporation. Glaukos, iStent®, iStent inject® and iStent inject® W are registered trademarks of Glaukos Corporation. PM-EU-0261
------
Long-Term Safety and Efficacy With iStent Technologies
Imran Masood, BSc, MB ChB, MRCS(Ed) FRCOphth
1. Samuelson, Thomas W., et al. "Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results." Ophthalmology 126.6 (2019): 811-821.
2. Ahmed, Iqbal Ike K., et al. "Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma." American journal of ophthalmology 252 (2023): 17-25.
3. Nordstrom, Beth L., et al. "Persistence and adherence with topical glaucoma therapy." American journal of ophthalmology 140.4 (2005): 598-e1.
4. Samuelson, Thomas W., et al. "Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial." American Journal of Ophthalmology 229 (2021): 220-229
5. Masood, I et al. Poster presented at WGC, Rome. June 2023.

© 2023 Glaukos Corporation. Glaukos, iStent®, iStent inject® and iStent inject® W are registered trademarks of Glaukos Corporation. PM-EU-0260